<DOC>
	<DOC>NCT01723735</DOC>
	<brief_summary>Primary Objective: To assess the pharmacodynamic profile of alirocumab (SAR236553/REGN727) administered either alone or on top of ezetimibe or fenofibrate, based on low-density lipoprotein -cholesterol (LDL-C). Secondary Objectives: - To assess the pharmacodynamic profile of alirocumab administered either alone or on top of ezetimibe or fenofibrate, based on other lipid parameters. - To assess the pharmacokinetic profile of alirocumab administered either alone or on top of ezetimibe or fenofibrate.</brief_summary>
	<brief_title>Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects</brief_title>
	<detailed_description>Total duration of the study per subject (excluding screening) is about 22 weeks.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria : Healthy male /or female subjects, aged 18 to 65 years old, with LDLC &gt; 130 mg/dL not receiving lipid lowering therapy. Exclusion criteria: Healthy subjects with history or presence of clinically relevant illness. Subjects currently taking statins, ezetimibe or fenofibrate. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>